Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Iannitto E, et al. Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print. Haematologica. 2024. PMID: 38497158 Free article.
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C. Iannitto E, et al. Br J Haematol. 2018 Dec;183(5):755-765. doi: 10.1111/bjh.15641. Epub 2018 Nov 8. Br J Haematol. 2018. PMID: 30407629 Free article. Clinical Trial.
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.
Iannitto E, Luminari S, Tripodo C, Mancuso S, Cesaretti M, Marcheselli L, Merli F, Stelitano C, Carella AM, Fragasso A, Montechiarello E, Ricciuti G, Pulsoni A, Paulli M, Franco V, Federico M. Iannitto E, et al. Leuk Lymphoma. 2015;56(12):3281-7. doi: 10.3109/10428194.2015.1029925. Epub 2015 Jul 18. Leuk Lymphoma. 2015. PMID: 25791121 Clinical Trial.
Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi.
Merli F, Federico M, Avanzini P, Ilariucci F, Stelitano C, Iannitto E, Colombi M, Vallisa D, Santagati G, Picinini L. Merli F, et al. Among authors: iannitto e. Haematologica. 1998 Mar;83(3):217-21. Haematologica. 1998. PMID: 9573675 Free article. Clinical Trial.
How I diagnose and treat splenic lymphomas.
Iannitto E, Tripodo C. Iannitto E, et al. Blood. 2011 Mar 3;117(9):2585-95. doi: 10.1182/blood-2010-09-271437. Epub 2010 Nov 30. Blood. 2011. PMID: 21119113 Free article.
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A. Gallamini A, et al. Among authors: iannitto e. Haematologica. 2006 Apr;91(4):475-81. Haematologica. 2006. PMID: 16585014 Free article. Clinical Trial.
103 results